

Record-Breaking Endurance of 366 Marathons in 366 Days: A Case Study

Francis Ribeiro de Souza,¹ Renato Delascio Lopes,² Guilherme Wesley Peixoto da Fonseca,^{1,3} Rodrigo Bellio de Mattos Barretto,¹ Antonio Carlos Battaglia Filho,¹ Renata Margarida do Val,¹ Roberto Kalil-Filho,^{1,4} Maria-Janieire de Nazaré Nunes Alves¹

Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo,¹ São Paulo, SP – Brasil

Duke University Hospital,² Durham, North Carolina – USA

Escola de Educação Física e Esporte da Universidade de São Paulo,³ São Paulo, SP – Brazil

Hospital Sírio Libanês,⁴ São Paulo, SP – Brazil

Abstract

Background: A Brazilian athlete has proposed setting a new world record for consecutive marathons by running 366 marathons in 366 consecutive days. The impact of such a feat on the cardiovascular system is unknown.

Objective: To monitor the cardiovascular system to assess the athlete's cardiovascular adaptations or maladaptations over the period.

Methods: During the pre-study evaluation, we conducted the pre-participation clinical evaluation (PPE) composed of anamnesis, electrocardiogram, blood test, and functional capacity by maximum cardiopulmonary exercise test (CPET). At follow-up, serial CPET, body composition assessment, blood sample, and echocardiogram were periodically performed for 12 months.

Results: At PPE, male, 43-year-old, height: 1.83 m, weight: 76.9 kg, maximum oxygen consumption (VO_2max): 52 ml/kg/min, body fat: 12.6%, systolic and diastolic blood pressure: 120/80 mmHg, blood glucose: 92 mg/dL, total cholesterol (TC): 185 mg/dL, high-sensitivity C-reactive protein (hs-CRP): 0.08 mg/dL, creatine phosphokinase (CPK): 183 U/L, and high-sensitivity troponin T (hs-TnT): 7.1 ng/L. At follow-up, the average of VO_2max remained at 48.7 ± 1.2 ml/kg/min, left ventricular ejection fraction (LVEF) at $62 \pm 2\%$, LV strain global longitudinal at $19 \pm 1\%$, LV mass index at 83 ± 7 g/m², hs-CRP at 0.07 ± 0.01 mg/L, CPK at 169 ± 36 U/L, hs-TnT at 8.2 ± 1.4 ng/L, and no malignant arrhythmias were observed.

Conclusion: The athlete's cardiovascular system had adapted to an extremely high volume of consecutive marathons at moderate intensity for one year and remained functioning at normal range. In addition, the athlete set a new world record for most consecutive days to run a marathon, recognized by Guinness World Records.

Keywords: Marathon Running; Cardiovascular System; Physical Endurance.

Introduction

Endurance performance is determined by maximum oxygen consumption (VO_2max), running economy, and lactate threshold.¹ Through regular physical training, it is possible to develop a running economy, especially in long-distance runners.² Impressively, Robison and collaborators reported the physiological profile of a 70-year-old male marathoner who completed a marathon in 2:54:23 on December 15, 2018, breaking the world record time for men over the age of 70 years.³

A Belgian athlete ran a marathon per day for 365 days in 2010, accomplishing one of the greatest feats in the history of sport.⁴ However, no clinical evaluation was carried out, and therefore, there is no information about the impact of daily marathons on the cardiovascular system.

A Brazilian amateur marathoner has proposed setting a new world record for consecutive marathons by running 366 marathons in 366 consecutive days. The impact of such a feat on the cardiovascular system remains unknown.

This study aimed to monitor the cardiovascular system regularly to assess any cardiovascular adaptations or maladaptation of the athlete throughout 366 consecutive marathons.

Material and methods

Study population

The local committee for the Protection of Human Subjects approved this study (CAAE: 61097822.0.0000.0068). We evaluated a Brazilian male marathoner (H.L.S.F.) who ran

Mailing Address: Francis Ribeiro de Souza / Maria Janieire Alves •

Av. Dr. Enéas Carvalho de Aguiar, 44, Comissão Científica - Centro de Pesquisa Clínica - Prof. Dr. Fulvio Pileggi, 1º andar. Sala 8. Postal Code 05403-900, São Paulo, SP - Brazil


E-mail: francis.ribeiro@hc.fm.usp.br, janieire.alves@incor.usp.br

Manuscript received December 12, 2024, revised manuscript February 12, 2025, accepted March 11, 2025

Editor responsible for the review: Ricardo Stein

DOI: <https://doi.org/10.36660/abc.20240838i>

Central Illustration: Record-Breaking Endurance of 366 Marathons in 366 Days: A Case Study


ABC Cardiol
Arquivos Brasileiros de Cardiologia


Arq Bras Cardiol. 2025; 122(5):e20240838

366 consecutive marathons in 366 days (from 28th August 2022 to 28th August 2023). The participant provided written informed consent.

Pre-study evaluation

The pre-participation clinical evaluation (PPE) was performed according to the Brazilian Society of Exercise and Sports Medicine.⁵ We performed an anamnesis, clinical examination composed by 12-lead resting electrocardiogram (ECG), maximum cardiopulmonary exercise test (CPET), bioelectrical impedance analysis, and blood test. In addition, the athlete presented an echocardiogram at PPE that was realized three months before our study.

Follow-up

We periodically repeated all tests. In the third month of follow-up, we also included measures of cardiac structure, left ventricle (LV) and right ventricle (RV) functions by echocardiography (ECHO) and repeated until the end of this study.

In addition, a multi-professional team composed of a dermatologist, endocrinologist, orthopedist, physiotherapist, nutritionist, physical trainer, and psychologist supported the athlete over the period.

Cardiopulmonary Exercise Test (CPET)

The CPET was performed using the maximum effort on automatic treadmill (Embramed – Model –Atlanta,

United States). A computerized respiratory gas analyzer (Vyntus CPX – Pulmonary Function/Cardiopulmonary Exercise Testing Instrument, Hoechberg, Germany) was used to evaluate pulmonary ventilation, maximum oxygen consumption (VO₂max), and carbon dioxide production (VCO₂). The variables were measured breath-by-breath. The first anaerobic threshold (AT) was identified by the V-slope technique observed at the first point of dissociation of the VE/VO₂ curves and the lowest value for partial oxygen pressure at the end of expiration (PetO₂), before this parameter started to increase progressively. The second ventilatory threshold (respiratory compensation point) was identified by the inflection in the VE/VCO₂ curves and the maximum value of partial pressure for CO₂ at the end of expiration (PetCO₂), before a progressive decrease in this response.⁶ Heart rate (HR) was continuously recorded during the CPET using a 12-lead electrocardiogram and software CardioSoft v6. The CPET was performed at PPE, after three months, and monthly until the end of the study. The athlete ran the marathons in the morning, and CPETs were performed in the afternoon.

Echocardiogram

The images were collected by the Vivid E9 (GE Healthcare; Oslo, Norway). The athlete underwent 2-dimensional ECHO. The 4-chamber color Doppler and then pulse-wave Doppler were used to assess peak flow velocities across the mitral valve. We assessed parasternal long-axis views, septal and LV posterior wall thickness

in diastole, as well as LV chamber dimensions at end-diastole and end-systole. LV volume at end-diastolic and LV volume at end-systolic were assessed by apical 2- and 4-chamber views, which then allowed the estimation of stroke volume and left ventricle ejection fraction by Simpsons biplane method. Specific speckle-tracking software was used to estimate strain in all segments. All the images were collected according to the American Society of Echocardiography and the European Association of Cardiovascular Imaging.⁷ The first echo was performed 3 months after starting the study and periodically evaluated during the follow-up. The athlete ran the marathons in the morning, and echocardiograms were performed in the afternoon, always before the CPET.

Statistical analysis

Data are periodically presented based on evaluations and reported as mean \pm standard deviation (SD). The Statistical Package for Social Science (SPSS) version 23 was used to describe the variables.

Results

Pre-study evaluation

At PPE, 43-year-old, height: 1.83 m, weight: 76.9 kg, VO_2max : 52 ml/kg/min, body fat: 12.6%, systolic and diastolic blood pressure: 120/80 mmHg, blood glucose: 92 mg/dL, total cholesterol: 185 mg/dL, high-sensitivity C-reactive protein (hs-CRP): 0.08 mg/dL, creatine phosphokinase (CPK): 183 U/L, and high-sensitivity troponin T (hs-TnT): 7.1 ng/L.

In the first CPET, we used a specific ramp protocol (protocol: velocity 1) composed of increments of velocity and inclination each minute until the athlete's exhaustion (protocol details are described in supplementary material). The CPET duration was 10 minutes, the maximum velocity was 8.2 mph, 11.0% of inclination, VO_2max was 52.0 ml/kg/min, and the respiratory exchange ratio (RER) was 1.11. $\text{RER} \geq 1.10$ is considered a maximum test.⁶ The first AT was around 6.0 mph, and the HR was 150 bpm. The athlete was instructed to run the marathons at moderate intensity close to the first AT obtained by maximum CPET.

Follow-up

Clinical measures, body composition, biomarkers, and lipids profile are described in Table 1. These variables showed minimal physiological variations with no abnormal alterations. The resting HR was measured from CPET in the supine position after 2 minutes at baseline. The slight variation of resting HR may be related to pre-test anxiety.

The mean HR during the marathons was 140 ± 10 bpm, VO_2max remained at 49 ± 1 ml/kg/min, and pulmonary ventilation at 113 ± 4 L/min (Figure 1 A-B). From the CPET performed in January, we changed the protocol velocity 1 to protocol D to avoid the risk of muscle injury during CPET (supplementary material). This alteration could explain a slight drop in VO_2max and

ventilation. However, the athlete reached the maximum HR ($\text{HR} > 95\%$ predicted by age), and the RER was 1.08 ± 0.04 . Moreover, no signs of malignant arrhythmia and cardiovascular disorders were found during CPET, which assured us of the safety of continuing with the marathons. Furthermore, no significant changes between 12-lead ECG in the pre-study and 12-lead ECG at the end of the study were found (Figure 1B-C).

Cardiac structural variables, LV systolic function, RV systolic function, and myocardial work are described in Table 2. These variables showed minimal physiological variations within normal values.

In addition, the athlete had been involved in a muscle strengthening program based on weight training, mobility, flexibility, and stretching, twice a week, 2 to 3 sets to each muscle group with 15 repetitions at 70% of your maximum capacity during the marathons. The average daily calorie consumption was 4.716 ± 806 kilocalories (composed by carbohydrate $68 \pm 6\%$, lipids $17 \pm 5\%$, and protein $15 \pm 4\%$). Psychological work was also performed by the athlete, composed of 102 therapy sessions that assessed personal, motivational, resilience, ability to deal with frustration, family involvement, routine division, and adaptation over the period. In January 2023, the athlete was diagnosed with pubalgia and needed physical therapy treatment that remained until August 2023. The athlete documented all the marathons and distances using two smart watches simultaneously and used 27 pairs of running shoes. The average marathon time was 5 hours, 8 minutes, and 28 seconds; the fastest was 3 hours, 54 minutes, and 48 seconds; and the slowest was 10 hours, 21 minutes, and 6 seconds.

Discussion

To the best of our knowledge, this is the first study to monitor the cardiovascular system regularly in a very comprehensive manner in a male marathoner who ran 366 daily consecutive marathons. We hypothesized that the athlete would undergo physiological cardiovascular adaptations or maladaptations due to the high volume of running in one year. Interestingly, the athlete presented minimal physiological variations with no abnormal cardiovascular changes in one year. In addition, the athlete set a new world record of running 366 consecutive marathons in 366 days, recognized by Guinness World Records.⁸

First, we performed PPE to identify the presence of unknown cardiovascular diseases that could be incompatible with this study. The athlete had no family history of sudden cardiac death or hypertrophic cardiomyopathy and showed a great cardiovascular, respiratory, hemodynamic, and physical response during CPET.⁹ The 12-lead resting ECG, blood test, and blood pressure were within the normal limits. Furthermore, the athlete presented an echocardiogram with normal values that was realized three months before our study.

Exercise training is a powerful trigger to promote structural and functional remodeling of the heart.¹⁰ However, there is increasing recognition of the impact of

Table 1 – Clinical measures, body composition, biomarkers, and lipids profile

Variables	August 2022, Pre-study	2022 November	2023 February	2023 May	2023 July	August 2023, End of Study	Mean - SD	Normal Value or Range
Clinical								
SBP (mmHg)	120	110	110	110	120	120	115 ± 5	< 120
DBP (mmHg)	90	80	80	80	80	80	80 ± 5	< 80
Resting HR (bpm)	90	81	96	80	67	77	82 ± 10	< 100
Body composition								
Weight (kg)	76.9	74.2	71.4	71.0	71.7	70.5	72.6 ± 2.5	-
Height (m)	1.83	1.83	1.83	1.83	1.83	1.83	1.83	-
BMI (kg/m ²)	23.0	22.2	21.3	21.2	21.4	21.1	21.7 ± 0.7	18.9 - 24.9
Lean mass (kg)	67.2	65.5	64.2	63.9	64.7	63.6	64.9 ± 1.3	-
Fat mass (kg)	9.7	8.7	7.2	7.1	7.0	6.9	7.8 ± 1.2	-
Fat mass (%)	12.6	11.7	10.1	10.0	9.7	9.8	10.7 ± 1.2	< 20.0
Biomarkers and Lipids Profile								
hs-CRP (mg/L)	0.08	0.08	0.06	0.08	0.07	0.06	0.07 ± 0.01	< 0.1
CPK (U/L)	183	184	190	190	183	104	169 ± 36	46 - 171
hs-TnT (ng/L)	7.1	6.0	8.8	10.0	8.0	9.0	8.2 ± 1.4	< 16.8
Creatinine (mg/dL)	1.14	1.01	1.15	1.02	0.99	1.06	1.06 ± 0.07	0.7 - 1.30
Potassium (mmol/L)	4.8	4.3	4.5	4.3	4.7	4.5	4.5 ± 0.2	3.5 - 5.1
Sodium (mmol/L)	137	136	141	138	139	140	139 ± 2	136 - 145
NT-proBNP (pg/mL)	-	-	22.1	24.4	10.8	14.4	17.9 ± 6.4	< 125
TC (mg/dL)	185	180	-	199	191	204	192 ± 10	< 190
LDL (mg/dL)	111	111	-	130	126	132	122 ± 10	< 130
HDL (mg/dL)	53	48	-	52	49	56	52 ± 3	> 40
TG (mg/dL)	99	81	-	75	64	78	79 ± 13	< 150

HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; hs-CRP: high-sensitivity C-reactive protein; CPK: creatine phosphokinase; hs-TnT: high-sensitivity troponin T; NT-ProBNP: N-terminal proBNP; LDL: low density lipoprotein; HDL: high density lipoprotein; TG: triglycerides; TC: total cholesterol.

prolonged exercise training on cardiac remodeling, which may eventually mimic certain pathological conditions.¹¹ During the follow-up, we periodically monitored the athlete to guarantee his safety, and if eventually the athlete presented any pathological condition that could harmfully progress with potential risk to his life, the study would have been interrupted. Interestingly, the athlete presented minimal physiological variations in cardiac structure, LV function, and RV function, with no signs of overtraining or altered inflammation over the period.¹²

Controversially, exercise training may be associated with an increased risk of ventricular and atrial arrhythmias.¹³ Moreover, exercise intensity but not volume may be associated with increased coronary calcification in athletes.¹⁴ In our study, the athlete was instructed to run

the marathons at moderate intensity (around first AT), and no signs of altered ECG suggesting ischemia and malignant arrhythmias were observed during CEPT.

Studies to understand physiological responses in champion athletes with performance records have been carried out for several years.¹ VO₂max is a marker of cardiac respiratory and circulatory response, which is one of the main factors that contribute to endurance performance.¹ Furthermore, steady-state oxygen consumption is often referred to as a running economy. The 70-year-old male marathoner, who ran a marathon in less than 3 hours in 2018, breaking the world record for men over 70, performed a single CPET and demonstrated a VO₂max of approximately 46.9 ml/kg/min. This value was exceptional for his age, as the average VO₂max for an age-matched male is




Figure 1 – Follow-up of maximum oxygen consumption (VO₂max) and pulmonary ventilation by cardiopulmonary exercise test (CPET), (Fig. 1 A-B, respectively). 12-lead resting electrocardiogram (ECG) in the pre-study and ECG at the end of the study (Fig. 1B-C, respectively).

around 26 ml/kg/min.³ In contrast, no clinical evaluation was performed on the Belgian athlete who ran 365 consecutive marathons, highlighting the uniqueness and significance of our findings.

In our study, the CPETs were performed in the afternoon, after the athlete had completed a marathon earlier in the day. This may have influenced performance metrics, including VO₂max, ventilatory thresholds, and cardiac responses, potentially underestimating the athlete's true maximal capacity. However, the athlete showed an optimal VO₂max and sustained adaptations in physical capacity throughout the 12 months (Central Illustration).

Clinical implication

These results highlight the importance of a careful cardiovascular assessment in athletes undergoing endurance exercise and provide unique insight into the relationship between high-volume, intensity marathons and cardiovascular adaptations.

Limitations

We recognize some limitations in our study. From the CPET performed in January until August, we adjusted the protocol velocity to reduce the risk of muscle injury during CPET. This alteration may explain a slight drop in VO₂max and ventilation,

which could limit the scientific utility of VO₂max as a follow-up variable. However, VO₂max remained around 49 ml/kg/min, suggesting a sustained functional capacity. The Echo was not performed in the pre-evaluation study because the athlete presented an echocardiogram with normal values at PPE that was realized three months before our study. However, during the follow-up, the parameters were within the normal limits. This study relates to one male marathoner, and these results should be interpreted with caution when extrapolating to a broader population.

Conclusion

In conclusion, the athlete's cardiovascular system had adapted to an extremely high volume of consecutive marathons and remained functioning at a normal range. In addition, the athlete set a new world record of running 366 consecutive marathons in 366 days, recognized by Guinness World Records.

Acknowledgment

We thank and congratulate the Brazilian athlete Hugo Leonardo Sousa Farias (H.L.S.F) for this incredible feat in the history of sport recognized by Guinness World Records (4th June 2024). We thank the multi-professional team, Daniela Farias (dermatologist), Silvia Machado (endocrinologist), Rogerio Savoy (orthopedist) Fernanda Bosi (orthopedist),

Table 2 – Cardiac structural, left ventricular systolic function, right ventricular systolic function, and myocardial work

Variables	October After 3 months	2022 November	2023 March	2023 June	2023 July	August,2023 End of Study	Mean - SD	Normal Value or Range
Cardiac structures								
Aortic root (cm)	3.4	3.3	3.4	3.3	3.3	3.4	3.4 ± 0.1	3.0 - 3.7
RA diameter (cm)	3.8	3.5	3.6	3.3	3.4	3.3	3.5 ± 0.1	3.0 - 4.0
RV basal (cm)	3.8	3.8	3.4	4.0	4.0	3.3	3.7 ± 0.3	2.5 - 4.1
RV mid (cm)	3.1	3.1	2.8	3.1	3.3	2.7	3.0 ± 0.2	1.9 - 3.5
Interventricular septum (cm)	0.9	0.8	0.9	0.8	0.9	0.8	0.9 ± 0.1	0.6 - 1.0
LV posterior wall thickness (cm)	0.9	0.8	0.8	0.8	0.8	0.8	0.8 ± 0.1	0.6 - 1.0
LV end-diastolic diameter (cm)	5.4	5.3	5.4	5.3	5.5	5.2	5.4 ± 0.1	4.2 - 5.8
LV end-systolic diameter (cm)	3.5	3.7	3.6	3.4	3.4	3.3	3.5 ± 0.1	2.5 - 4.0
LV diastolic volume (ml)	157	141	153	149	152	149	150 ± 5	80 - 150
LV systolic volume (ml)	62	63	58	59	60	62	61 ± 2	70
LV mass index (g/m ²)	92	77	87	78	90	76	83 ± 7	49 - 115
LA volume index (ml/m ²)	18	20	21	16	25	22	20 ± 3	< 34
Left ventricular systolic function								
LV ejection fraction (%)	60	62	62	61	60	59	61 ± 1	> 52
LV global longitudinal strain (%)	16	18	19	19	20	19	19 ± 2	≥ 18
Right ventricular systolic function								
TAPSE (mm)	21	24	24	22	24	25	23 ± 2	> 17
S' (cm/s)	14	13	14	14	15	19	15 ± 2	> 9.5
FAC (%)	49	46	53	51	46	50	49 ± 3	> 35
RV strain (%)	21	24	23	25	23	22	23 ± 1	> 20
Myocardial work								
GWE (%)	95	-	92	92	97	94	94 ± 2	> 96
GWW (mmHg)	84	-	182	154	49	106	115 ± 53	73 - 87
GWI (mmHg%)	1576	-	1953	1688	2148	2025	1878 ± 238	1907 - 2113
GCW (mmHg%)	1680	-	2194	1987	2224	2209	2059 ± 233	2186 - 2369

RA: right ventricle; RV: right ventricle; LV: left ventricle; LA: left atrium; TAPSE: tricuspid annular plane systolic excursion; S': tricuspid lateral annular systolic velocity wave; FAC: fractional area change; GWE: global work efficiency; GWW: global work wasted; GWI: global work index; GCW: global constructive work.

Vinicius Fomasari (physiotherapist), Bruna Castelani (nutritionist), Gisele Rossetto (physical trainer), Anito Alves (physical trainer), William Barbosa (physical trainer), Marta Minipoli (psychologist) for supporting the athlete over the period. We also thank the CardioMetabolic Evaluation Center and the team of Scientific Committee, Clinical Research Center Prof. Dr. Fulvio Pileggi (InCor, HCFMUSP) for coordinating this study.

Author Contributions

Conception and design of the research and Statistical analysis: Souza FR, Alves MJNN; Acquisition of data:

Souza FR, Barretto R, Battaglia Filho AC, Kalil-Filho R, Alves MJNN; Analysis and interpretation of the data: Souza FR, Lopes RD, Fonseca GWP, Barretto R, Battaglia Filho AC, Alves MJNN; Writing of the manuscript and Critical revision of the manuscript for content: Souza FR, Lopes RD, Fonseca GWP, Barretto R, Battaglia Filho AC, Val RM, Kalil-Filho R, Alves MJNN.

Potential conflict of interest

No potential conflict of interest relevant to this article was reported.

Sources of funding

There were no external funding sources for this study.

Study association

This study is not associated with any thesis or dissertation work.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the USP- Hospital das Clínicas de Medicina da Universidade de São Paulo - HCFMUSP under the protocol number CAAE:

61097822.0.0000.0068. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013.

Use of Artificial Intelligence

The authors did not use any artificial intelligence tools in the development of this work.

Availability of Research Data and Other Materials

The underlying content of the research text is contained within the manuscript.

References

1. Joyner MJ, Coyle EF. Endurance Exercise Performance: The Physiology of Champions. *J Physiol*. 2008;586(1):35-44. doi: 10.1113/jphysiol.2007.143834.
2. Barnes KR, Kilding AE. Running Economy: Measurement, Norms, and Determining Factors. *Sports Med Open*. 2015;1(1):8. doi: 10.1186/s40798-015-0007-y.
3. Robinson AT, Watso JC, Babcock MC, Joyner MJ, Farquhar WB. Record-Breaking Performance in a 70-Year-Old Marathoner. *N Engl J Med*. 2019;380(15):1485-6. doi: 10.1056/NEJMc1900771.
4. British Broadcasting Corporation. Belgian Stefaan Engels Completes Record 365th Marathon [Internet]. London: BBC News; 2011 [cited 2025 Mar 10]. Available from: <https://www.bbc.com/news/world-europe-12375646>.
5. Ghorayeb N, Stein R, Daher DJ, Silveira ADD, Ritt LEF, Santos DFPD, et al. The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019. *Arq Bras Cardiol*. 2019;112(3):326-68. doi: 10.5935/abc.20190048.
6. Balady CJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician's Guide to Cardiopulmonary Exercise Testing in Adults: A Scientific Statement from the American Heart Association. *Circulation*. 2010;122(2):191-225. doi: 10.1161/CIR.0b013e3181e52e69.
7. Lang RM, Badano LP, Mor-Avi V, Afzal J, Armstrong A, Ernande L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003.
8. Guinness World Records. Most Consecutive Days to Run a Marathon Distance (Male) [Internet]. London: Guinness World Records; 2023. Available from: <https://www.guinnessworldrecords.com/world-records/446698-most-consecutive-days-to-run-a-marathon-distance-male>.
9. Herdy AH, Caixeta A. Brazilian Cardiorespiratory Fitness Classification Based on Maximum Oxygen Consumption. *Arq Bras Cardiol*. 2016;106(5):389-95. doi: 10.5935/abc.20160070.
10. La Gerche A, Wasfy MM, Brosnan MJ, Claessen G, Fatkin D, Heidbuchel H, et al. The Athlete's Heart-Challenges and Controversies: JACC Focus Seminar 4/4. *J Am Coll Cardiol*. 2022;80(14):1346-62. doi: 10.1016/j.jacc.2022.07.014.
11. Maron BJ, Pelliccia A. The Heart of Trained Athletes: Cardiac Remodeling and the Risks of Sports, Including Sudden Death. *Circulation*. 2006;114(15):1633-44. doi: 10.1161/CIRCULATIONAHA.106.613562.
12. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17(4):412. doi: 10.1093/ehjci/jew041.
13. Heidbuchel H. The Athlete's Heart is a Proarrhythmic Heart, and What That Means for Clinical Decision Making. *Europace*. 2018;20(9):1401-11. doi: 10.1093/europace/eux294.
14. Aengevaeren VL, Mosterd A, Bakker EA, Braber TL, Nathoe HM, Sharma S, et al. Exercise Volume versus Intensity and the Progression of Coronary Atherosclerosis in Middle-Aged and Older Athletes: Findings from the MARC-2 Study. *Circulation*. 2023;147(13):993-1003. doi: 10.1161/CIRCULATIONAHA.122.061173.

*Supplemental Materials

For additional information, please click here.



This is an open-access article distributed under the terms of the Creative Commons Attribution License